Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)

Nona Biosciences will receive a total of up to $53 Million in upfront and near-term payments, with the potential for milestones of up to $1.05 billion plus royalties. Pfizer partnership expands Nona’s global network of collaborations, reinforcing its commitment to providing cutting-edge…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.